GHRP-6 Dosage, Protocol, and Reconstitution Guide
GHRP-6
GHRP-6 is a synthetic growth hormone secretagogue that activates the ghrelin receptor (GHSR-1a) and stimulates growth hormone (GH) release. Human research confirms a strong GH response, while also showing effects on other endocrine pathways including ACTH and cortisol.
How It Works
Ghrelin Receptor Activation → GH Release ↑ → GH / IGF-1 Pathway Signaling
GHRP-6 activates the growth hormone secretagogue receptor (GHSR-1a), stimulating GH release through both pituitary signaling and interaction with the body’s endogenous GHRH pathway. Human studies show that much of the GH response to GHRP-6 depends on endogenous GHRH activity.
Appetite stimulation is commonly associated with ghrelin-receptor activation and may be more noticeable with GHRP-6 than with some other GH secretagogues.
It is commonly discussed for recovery, weight gain, muscle support, and bulking phases.
It is less selective than Ipamorelin and may have more noticeable hunger, water retention, or hormone-related effects.
Because it has a short half-life, timing and consistency matter.
GHRP-6 Research Protocol
5 mg vial + 3.0 mL BAC Water → 1 unit = 16.7 mcg → GH Pulse + Appetite Support
Standard Setup
Vial
5 mg
Water
3.0 mL bacteriostatic water
Concentration
1.67 mg/mL
Conversion
1 unit = 16.7 mcg
Weeks 1–2
Start Phase
Dose100 mcg
Units6 units
Volume0.06 mL
Weeks 3–4
Build Phase
Dose150 mcg
Units9 units
Volume0.09 mL
Weeks 5–8
Peak Phase
Dose200 mcg
Units12 units
Volume0.12 mL
Weeks 9–12
Maintain Phase
Dose250 mcg
Units15 units
Volume0.15 mL
Protocol Details
FrequencyOnce daily
TimingBefore bed or between meals
Cycle Length8–12 weeks
Optional Longer UseOnly with planned breaks
Simple structure
GHRP-6 is commonly structured around appetite support, GH pulse signaling, recovery, and weight-gain phases. It is best approached gradually because hunger and water retention can be noticeable.
GHRP-6 is commonly structured around appetite support, GH pulse signaling, recovery, and weight-gain phases. It is best approached gradually because hunger and water retention can be noticeable.
Research context:
The dose progression shown above reflects a research/community framework and is not a standardized clinical GHRP-6 titration schedule. Published human studies used study-specific dosing and primarily intravenous administration.
The dose progression shown above reflects a research/community framework and is not a standardized clinical GHRP-6 titration schedule. Published human studies used study-specific dosing and primarily intravenous administration.
Advanced Research Protocol
Higher Research Range
Advanced
Dose200–300 mcg daily
Advanced Use:
Some research protocols use multiple daily pulses due to its short half-life, especially when appetite stimulation is desired. Higher frequency may increase hunger, water retention, and hormone-related side effects. However, specific fasting interval has not been established as part of a standardized clinical GHRP-6 regimen.
Some research protocols use multiple daily pulses due to its short half-life, especially when appetite stimulation is desired. Higher frequency may increase hunger, water retention, and hormone-related side effects. However, specific fasting interval has not been established as part of a standardized clinical GHRP-6 regimen.
How to Use GHRP-6 (Timing & Injection)
Use StyleGH pulse + appetite support
Research TimingBefore bed or between meals
Research FrequencyOnce daily standard
RouteSubcutaneous
Injection Notes
Subcutaneous injection
Common sites: abdomen, thigh, or upper arm
Can be taken fasted or before meals
Rotate injection sites regularly
Research Timing Notes
Before bed is commonly used for nighttime GH pulse support.
Between meals may be used when appetite stimulation is part of the goal.
Food timing may affect GH signaling, so fasted timing is often preferred in research-style discussions.
Because hunger can increase strongly, timing should match the goal of the protocol.
Reconstitution & Dosing (5 mg Vial)
Vial5 mg
Water3.0 mL
Concentration1.67 mg/mL
Conversion1 unit = 16.7 mcg
Dose Reference
6 units ≈ 100 mcg
9 units ≈ 150 mcg
12 units ≈ 200 mcg
15 units ≈ 250 mcg
18 units ≈ 300 mcg
Reconstitution Steps
Draw 3.0 mL bacteriostatic water
Inject slowly down vial wall
Gently swirl, do not shake
Allow powder to fully dissolve
Label with the reconstitution date
Refrigerate immediately after mixing
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (Unmixed Powder)
Short-term storage: keep refrigerated at 2–8°C
Long-term storage: freezing at −20°C is commonly preferred
Keep the vial sealed until ready to reconstitute
Protect from heat, sunlight, moisture, and repeated temperature swings
Avoid leaving lyophilized peptide at room temperature for extended periods
Do not repeatedly freeze and thaw the same vial
Store upright when possible and keep away from condensation
Estimated Unmixed Shelf Life
Refrigerated (2–8°C): commonly ~12–24 months when sealed and dry
Frozen (−20°C): commonly up to ~2–3 years when stored properly
Actual stability depends on supplier quality, handling, and storage conditions
Reconstituted (Mixed)
After mixing: refrigerate at 2–8°C
Use within ~4 weeks
Do not freeze after mixing
Discard if cloudy, discolored, or if particles appear
Best Practice
Lyophilized peptides are most stable when they stay cold, dry, sealed, and protected from light. Once mixed, the clock starts: keep refrigerated, avoid contamination, and use within the stated window.
Lyophilized peptides are most stable when they stay cold, dry, sealed, and protected from light. Once mixed, the clock starts: keep refrigerated, avoid contamination, and use within the stated window.
Research Cycle Length & Time Between Cycles
GH Secretagogue Research → Monitor Response → Reassess → Continue or Pause
Standard Research Cycle Structure
Cycle Length8–12 weeks
Primary PhaseDaily GH pulse + appetite support
GoalRecovery + weight support + muscle support
Established Cycle Length
No standardized cycle established
Time Between Research Cycles
Break4–8 weeks
Established Off-Cycle
No evidence-based off-cycle duration has been established
Reassessment may include GH / IGF-1 response, appetite changes, glucose-related markers, and tolerability.
Why cycle?
GHRP-6 stimulates GH through the ghrelin receptor and can produce strong hunger effects. Cycling helps maintain responsiveness, limits prolonged exposure, and gives a clear window to evaluate whether the protocol is helping.
GHRP-6 stimulates GH through the ghrelin receptor and can produce strong hunger effects. Cycling helps maintain responsiveness, limits prolonged exposure, and gives a clear window to evaluate whether the protocol is helping.
When to Stop or Pause Early
Hunger becomes excessive or hard to manage
Water retention becomes uncomfortable
Sleep quality worsens
Recovery benefits plateau or fade
You are continuing without a clear recovery, weight, or muscle-support goal
Important distinction:
Published human research establishes that GHRP-6 stimulates GH release, but it does not establish the fixed cycle lengths or mandatory receptor-reset breaks commonly discussed in peptide communities.
Published human research establishes that GHRP-6 stimulates GH release, but it does not establish the fixed cycle lengths or mandatory receptor-reset breaks commonly discussed in peptide communities.
Human Clinical Research
Human GH Response
Population
Healthy adult men
Administration
Intravenous GHRP-6
Finding
Strong GH response demonstrated
Role of Natural GHRH
Human research found that blocking endogenous GHRH eliminated most of the GH response to GHRP-6.
This suggests GHRP-6 works partly by interacting with the body’s existing GHRH signaling rather than acting as an isolated GH switch.
Other Endocrine Effects
Human studies have also documented ACTH and cortisol responses following GHRP-6 administration.
This means GHRP-6 should not be described as completely selective for growth hormone release.
Important research distinction:
Human studies confirm that GHRP-6 can stimulate GH release and interact with endogenous GHRH signaling. However, much of the published human research used intravenous administration. Common subcutaneous microgram protocols used in peptide communities have not been validated through comparable clinical trials for fat loss, muscle growth, recovery, or anti-aging outcomes.
Human studies confirm that GHRP-6 can stimulate GH release and interact with endogenous GHRH signaling. However, much of the published human research used intravenous administration. Common subcutaneous microgram protocols used in peptide communities have not been validated through comparable clinical trials for fat loss, muscle growth, recovery, or anti-aging outcomes.
Monitoring During Use
Appetite changes
Body weight trends
Recovery and soreness
Sleep quality
Water retention
Signs of reduced response over time
Benefits
Demonstrated GH-releasing activity in human research
Interacts with endogenous GHRH signaling
GH / IGF-1 signaling is involved in metabolism, tissue maintenance, and body-composition pathways
Ghrelin-receptor activity may also influence appetite and other neuroendocrine pathways
Potential Side Effects
Increased appetite may occur through ghrelin-receptor signaling
Human research has documented ACTH and cortisol responses
Potential effects on glucose regulation and insulin sensitivity
Injection-site irritation may occur with injectable research formulations
FDA safety context:
FDA has identified potential safety concerns with compounded GHRP-6, including immunogenicity and peptide-related impurity concerns. FDA also notes limited safety information and potential effects on cortisol and blood glucose related to decreased insulin sensitivity.
FDA has identified potential safety concerns with compounded GHRP-6, including immunogenicity and peptide-related impurity concerns. FDA also notes limited safety information and potential effects on cortisol and blood glucose related to decreased insulin sensitivity.
Research Stacking Strategies
GH Pulse Support → Recovery + Appetite Layering → Avoid Overlap Without a Plan
Common Pairing Approaches
Classic Stack: GHRP-6 + CJC-1295 (NO DAC)
Mass Phase: GHRP-6 + IGF-1 LR3
Recovery: GHRP-6 + BPC-157
GH Pathway Research: GHRP-6 + a GHRH analog is commonly discussed because the pathways can interact to produce a larger GH response.
What to Avoid
Stacking multiple GHRPs without a clear reason
Using appetite-stimulating compounds during aggressive fat-loss phases unless planned
Running long continuous cycles without breaks
Ignoring water retention, sleep, and hunger signals
Simple rule
GHRP-6 is best suited for phases where appetite, recovery, and weight support are useful. If appetite stimulation is not desired, a more selective option may fit better.
GHRP-6 is best suited for phases where appetite, recovery, and weight support are useful. If appetite stimulation is not desired, a more selective option may fit better.
Important Notes
Strongest appetite stimulation among GHRPs
Less selective than Ipamorelin
Short half-life means timing matters
Best suited for bulking, recovery, or weight-support phases
Fasted timing is often preferred for cleaner GH signaling
Best used strategically, not continuously
Important Disclaimer
GHRP-6 is not FDA-approved and is intended for research purposes only.
Research & References
Primary Research
- Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. Growth Hormone (GH)-Releasing Peptide-6 Requires Endogenous Hypothalamic GH-Releasing Hormone for Maximal GH Stimulation. Journal of Clinical Endocrinology & Metabolism. 1998.
- Micic D, Mallo F, Peino R, et al. Regulation of Growth Hormone Secretion by the Growth Hormone-Releasing Hexapeptide (GHRP-6). Journal of Pediatric Endocrinology. 1993.
- Cabrales A, Gil J, Fernández E, et al. Pharmacokinetic Study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in Nine Male Healthy Volunteers. European Journal of Pharmaceutical Sciences. 2013.
Research Note: GHRP-6 reliably stimulates pulsatile growth hormone release in human clinical studies, but it also raises cortisol, prolactin, and appetite more than newer secretagogues such as Ipamorelin. The pharmacokinetic data above come from clinical/research-dose studies—not from the specific self-administration protocols circulating in fitness communities—so treat dosing charts as extrapolated rather than clinically validated.
Comments
Post a Comment